Publications by authors named "Adrian Mander"

Claim this Profile
M
Multivariate Bayesian Dynamic Borrowing for Repeated Measures Data With Application to External Control Arms in Open-Label Extension Studies.
Benjamin F Hartley, Matthew A Psioda, Adrian P Mander

Biom J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial.
Chantal Mathieu, Julie Wych, A Emile J Hendriks, Lisa Van Ryckeghem, Timothy Tree, Adrian P Mander

Lancet· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A personalized and systematically designed adherence intervention improves photoprotection in adults with xeroderma pigmentosum (XP): results of the XPAND randomized controlled trial.
Jessica Walburn, Sam Norton, Robert Sarkany, Martha Canfield, Kirby Sainsbury, Adrian P Mander

Br J Dermatol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CONSORT-DEFINE explanation and elaboration: recommendations for enhancing reporting quality and impact of early phase dose-finding clinical trials.
Jan Rekowski, Christina Guo, Olga Solovyeva, Munyaradzi Dimairo, Mahtab Rouhifard, Adrian Mander

EClinicalMedicine· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols.
Moreno Ursino, Guillermo Villacampa, Jan Rekowski, Munyaradzi Dimairo, Olga Solovyeva, Adrian Mander

EClinicalMedicine· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficient Study Design and Analysis of Longitudinal Dose-Response Data Using Fractional Polynomials.
Benjamin F Hartley, Dave Lunn, Adrian P Mander

Pharm Stat· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigating the effect of verapamil on preservation of beta-cell function in adults with newly diagnosed type 1 diabetes mellitus (Ver-A-T1D): protocol for a randomised, double-blind, placebo-controlled, parallel-group, multicentre trial.
Julie Wych, Martina Brunner, Rachel Stenson, Piotr Jaroslaw Chmura, Thomas Danne, Adrian Paul Mander

BMJ Open· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
C286, an orally available retinoic acid receptor β agonist drug, regulates multiple pathways to achieve spinal cord injury repair.
Maria B Goncalves, Yue Wu, Earl Clarke, John Grist, Julien Moehlin, Adrian P Mander

Front Mol Neurosci· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Handling Incomplete or Late-Onset Toxicities in Early-Phase Dose-Finding Clinical Trials: Current Practice and Future Prospects.
Zhulin Yin, Adrian P Mander, Johann S de Bono, Haiyan Zheng, Christina Yap

JCO Precis Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel retinoic acid receptor-β agonist for treatment of spinal cord injury, in male healthy participants.
Maria B Goncalves, Tim Mant, Jörg Täubel, Earl Clarke, Hana Hassanin, Adrian P Mander

Br J Clin Pharmacol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance.
Christina Yap, Jan Rekowski, Moreno Ursino, Olga Solovyeva, Dhrusti Patel, Adrian Mander

BMJ· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance.
Christina Yap, Olga Solovyeva, Johann de Bono, Jan Rekowski, Dhrusti Patel, Adrian Mander

BMJ· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study.
Olga Solovyeva, Munyaradzi Dimairo, Christopher J Weir, Siew Wan Hee, Aude Espinasse, Adrian Mander

BMC Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SPIRIT and CONSORT extensions for early phase dose-finding clinical trials: the DEFINE (DosE-FIndiNg Extensions) study protocol.
Aude Espinasse, Olga Solovyeva, Munyaradzi Dimairo, Christopher Weir, Thomas Jaki, Adrian Mander

BMJ Open· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum. Innovative Designs and Logistical Considerations for Expedited Clinical Development of Combination Disease-Modifying Treatments for Type 1 Diabetes. Diabetes Care 2022;45:2189-2201.
Randy L Anderson, Linda A DiMeglio, Adrian P Mander, Colin M Dayan, Peter S Linsley

Diabetes Care· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimised point estimators for multi-stage single-arm phase II oncology trials.
Michael J Grayling, Adrian P Mander

J Biopharm Stat· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subgroup analyses in randomized controlled trials frequently categorized continuous subgroup information.
S Faye Williamson, Michael J Grayling, Adrian P Mander, Nurulamin M Noor, Joshua S Savage

J Clin Epidemiol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Innovative Designs and Logistical Considerations for Expedited Clinical Development of Combination Disease-Modifying Treatments for Type 1 Diabetes.
Randy L Anderson, Linda A DiMeglio, Adrian P Mander, Colin M Dayan, Peter S Linsley

Diabetes Care· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A stochastically curtailed single-arm phase II trial design for binary outcomes.
Martin Law, Michael J Grayling, Adrian P Mander

J Biopharm Stat· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes.
David B Dunger, Sylvaine F A Bruggraber, Adrian P Mander, M Loredana Marcovecchio, Timothy Tree

Trials· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two-Stage Single-Arm Trials Are Rarely Analyzed Effectively or Reported Adequately.
Michael J Grayling, Adrian P Mander

JCO Precis Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The need for reporting guidelines for early phase dose-finding trials: Dose-Finding CONSORT Extension.
Christina Yap, Alun Bedding, Johann de Bono, Munyaradzi Dimairo, Aude Espinasse, Adrian Mander

Nat Med· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes.
Charlotte S Wilhelm-Benartzi, Sarah E Miller, Sylvaine Bruggraber, Diane Picton, Mark Wilson, Adrian Mander

BMJ Open· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accounting for variation in the required sample size in the design of group-sequential trials.
Michael J Grayling, Adrian P Mander

Contemp Clin Trials· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel equivalence probability weighted power prior for using historical control data in an adaptive clinical trial design: A comparison to standard methods.
Maxine Bennett, Simon White, Nicky Best, Adrian Mander

Pharm Stat· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis